This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
NAD+ metabolism-based immunoregulation and therapeutic potential
Cell & Bioscience Open Access 10 May 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Abdellatif, M. et al. Nicotinamide for the treatment of heart failure with preserved ejection fraction. Sci. Transl. Med. 13, eabd7064 (2021)
Related article
Mishra, S. & Kass, D. A. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-020-00480-6 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Robson, A. Restoration of NAD+ levels as a therapy for HFpEF. Nat Rev Cardiol 18, 307 (2021). https://doi.org/10.1038/s41569-021-00535-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-021-00535-2
This article is cited by
-
NAD+ metabolism-based immunoregulation and therapeutic potential
Cell & Bioscience (2023)